GLP-1 in Psoriasis and Eczema: TNF-Inhibitor and Dupixent Stacking

Psoriasis affects roughly 7.5 million US adults; atopic dermatitis (eczema) reaches a further 10% of the adult population. Both diseases overlap heavily with obesity — Armstrong's 2012 meta-analysis^[1] placed the odds ratio of obesity in moderate-to-severe psoriasis at roughly 1.7–2.2, and the Jensen 2013 randomized weight- loss trial^[3] showed that a 15 kg drop produced a clinically meaningful PASI improvement on top of standard therapy. GLP-1 receptor agonists land on this picture from two directions: the weight-loss lever that already has Level-1 evidence in psoriasis, and a smaller but interesting direct anti-inflammatory signal (Buysschaert 2014^[5], Mazidi 2017^[9]). This article walks through what the published evidence supports for stacking semaglutide or tirzepatide on top of TNF inhibitors, IL-23 biologics, IL-17 biologics, JAK inhibitors, dupilumab, and the rest of the modern dermatology toolkit.

The honest summary

• Weight loss helps PASI — this is Level-1 evidence. The Jensen 2013 JAMA Dermatology randomized trial^[3] showed a low-energy diet producing ~15 kg loss cut PASI by roughly 2 points more than the control arm at 16 weeks; the 64-week follow-up (Jensen 2016^[4]) confirmed the benefit persisted in patients who kept the weight off.
• The direct GLP-1 signal in psoriasis is real but smaller than the weight-loss signal. Two positive liraglutide case-series in diabetic psoriasis patients (Buysschaert 2014^[5], Faurschou 2014^[6]) showed PASI and DLQI improvements that correlated with dermal γδ T-cell reduction — but the Faurschou 2015 RCT^[7] in glucose-tolerant patients was negative. The Ku 2024 meta-analysis^[8] pooled the available data and concluded the effect is plausible but modest, with most of the magnitude attributable to the weight-loss pathway.
• No pharmacokinetic interaction with any approved dermatology biologic. Adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade), guselkumab (Tremfya), risankizumab (Skyrizi), secukinumab (Cosentyx), ixekizumab (Taltz), ustekinumab (Stelara), dupilumab (Dupixent), tralokinumab (Adbry), and lebrikizumab (Ebglyss) are all subcutaneous or IV biologics with no oral absorption to share with a GLP-1. Continue all of them across titration.
• Oral JAK inhibitors deserve a small note. Tofacitinib (Xeljanz), upadacitinib (Rinvoq), deucravacitinib (Sotyktu), and abrocitinib (Cibinqo) are oral — the GLP-1 gastric-emptying delay can blunt Cmax by a clinically minor amount but no dose change is required.

Why obesity and psoriasis travel together

Armstrong's 2012 systematic review^[1] pooled 16 observational studies and placed the odds ratio of obesity in psoriasis at roughly 1.66 overall and ~2.23 in severe disease. The mechanism runs both directions. Adipose tissue is a TNF-α and IL-6 source — the same cytokines that drive the psoriatic IL-23/IL-17 axis described in Armstrong's 2020 JAMA review^[2]. Conversely, the inflammatory burden of moderate-to-severe psoriasis worsens insulin resistance and accelerates cardiometabolic comorbidities. Among moderate-to-severe psoriasis patients, the share who meet the BMI ≥ 30 obesity threshold lands in the 30–40% range across published cohorts — well above the ~13% obesity rate of the general matched population.

Atopic dermatitis (eczema) shows a weaker but still real obesity association. The mechanism is less the inflammatory cytokine overlap and more the dehydration and skin-barrier compromise that can worsen with high-dose GLP-1 nausea- induced fluid loss. Practical pathway: GLP-1 is not contraindicated, but emphasize hydration and continue topical emollients aggressively during titration.

The Jensen weight-loss randomized trial

Jensen 2013 (JAMA Dermatology^[3]) randomized 60 adults with moderate-to-severe psoriasis and BMI 27–45 to a low-energy diet (800–1,200 kcal/day, ~15 kg loss) or ordinary healthy-eating control for 16 weeks. The intervention arm dropped PASI by a median of ~2.3 points more than control (P = 0.06, mean DLQI also improved). The 64-week follow-up (Jensen 2016, AJCN^[4]) tracked the cohort through weight regain and showed PASI benefit persisted in patients who kept weight off, decayed in those who regained. The pattern is consistent with the broader weight-loss-and- autoimmune literature: lose the weight, the inflammation signal drops; regain it, the signal returns.

The applied translation for GLP-1 patients is straightforward. STEP-1 (semaglutide) and SURMOUNT-1 (tirzepatide) produce weight losses of −14.9% and −20.9% respectively — equal to or larger than Jensen's low-energy diet and sustained for longer, since GLP-1 maintenance is easier than dietary maintenance. The expected PASI benefit from the weight-loss pathway alone is at least as large as Jensen 2013 showed.

The direct GLP-1 signal: case-series, RCT, and meta-analysis

Buysschaert 2014^[5] followed seven obese type-2-diabetic patients with chronic plaque psoriasis through 10 weeks of liraglutide. Mean PASI dropped from 4.8 to 3.5; the more interesting finding was a 50% reduction in dermal γδ T-cells on lesional skin biopsy — a mechanistic anchor for direct anti-inflammatory effect independent of weight loss. Faurschou 2014^[6] reported a parallel positive case-series.

The cold water came from Faurschou 2015^[7], an RCT in 20 glucose-tolerant adults with moderate-to-severe psoriasis randomized to liraglutide 1.8 mg or placebo for 8 weeks. No PASI difference. The negative result disciplines the case-series enthusiasm: in non-diabetic patients without meaningful weight loss over 8 weeks, the direct anti-inflammatory signal does not produce a measurable PASI change.

Ku 2024^[8] pooled the available studies in an updated meta-analysis and concluded the published data support a modest beneficial effect, with most of the magnitude attributable to weight loss and a smaller plausible direct component. The CRP-reduction meta-analysis of GLP-1 therapy in diabetes (Mazidi 2017^[9]) is the cleanest mechanistic anchor: pooled CRP dropped by roughly 1.3 mg/L, consistent with a real systemic anti-inflammatory effect that may or may not reach the IL-23/IL-17 axis at a clinically meaningful dose.

The dermatology biologic stack: what continues, what to watch

• TNF-α inhibitors — adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade), certolizumab pegol (Cimzia), golimumab (Simponi). All subcutaneous or IV. No PK interaction with GLP-1. Continue across titration. The TNF class is also the most obesity-sensitive in terms of efficacy — the published data show better response rates after weight loss, so the GLP-1 may indirectly improve TNF-class outcomes.
• IL-23 inhibitors — guselkumab (Tremfya), risankizumab (Skyrizi), tildrakizumab (Ilumya). IL-12/23: ustekinumab (Stelara). All subcutaneous. No PK interaction. The IL-23 class has the best PASI outcomes in the current Armstrong 2020 review^[2] and is the most common stacking partner.
• IL-17 inhibitors — secukinumab (Cosentyx), ixekizumab (Taltz), brodalumab (Siliq), bimekizumab (Bimzelx). All subcutaneous. No PK interaction. The IL-17 class is dose-stable across weight; no GLP-1- driven dose change is needed.
• JAK inhibitors — tofacitinib (Xeljanz), upadacitinib (Rinvoq), deucravacitinib (Sotyktu), abrocitinib (Cibinqo). Oral. Gastric-emptying delay can blunt Cmax modestly — clinical guidance does not require dose adjustment.
• Atopic dermatitis biologics — dupilumab (Dupixent, IL-4/13), tralokinumab (Adbry, IL-13), lebrikizumab (Ebglyss, IL-13). All subcutaneous. No PK interaction. Hydration emphasis is the only practical addition during GLP-1 titration.
• Topicals — topical steroids, calcineurin inhibitors (tacrolimus, pimecrolimus), calcipotriol, tapinarof, roflumilast. None systemically absorbed at clinically meaningful levels. Continue unchanged.

Magnitude: PASI score change at 24 weeks by intervention

Special populations

Psoriatic arthritis (PsA). The same biologic classes apply, and the obesity signal is, if anything, stronger — obesity worsens PsA response rates to TNF inhibitors. GLP-1 titration is identical; coordinate with rheumatology so methotrexate dosing is not adjusted during the GLP-1 ramp.

Hidradenitis suppurativa (HS). HS is strongly obesity-associated, and emerging case-series suggest weight loss meaningfully improves Hurley stage and flare frequency. There is no published RCT of GLP-1 in HS yet, but the mechanistic rationale (obesity-driven TNF burden + mechanical friction in intertriginous skin) makes the weight-loss pathway plausible.

Pediatric and adolescent psoriasis. GLP-1 coverage in adolescents 12 and older is approved for liraglutide (Saxenda) and semaglutide (Wegovy) for obesity; no dedicated pediatric psoriasis-and-GLP-1 trial exists. Defer to the prescribing pediatric dermatologist and endocrinologist together.

The practical pathway

1. Continue all psoriasis or eczema biologics unchanged. No washout, no dose change, no interaction concern. Hand the GLP-1 prescriber the current biologic name and dose so it is documented.
2. Standard slow GLP-1 titration. The 0.25 mg to 2.4 mg semaglutide ladder (Wegovy) or the 2.5 mg to 15 mg tirzepatide ladder (Zepbound) does not change for psoriasis patients. Anti-emetic support during weeks 5–9 is the usual practice.
3. Track PASI and DLQI quarterly. Most patients should see a measurable PASI drop by month 6 driven by the weight-loss pathway; the direct anti-inflammatory contribution, if any, is small.
4. Hydration emphasis for eczema patients. GLP-1 nausea and reduced oral intake can produce mild dehydration that worsens atopic dermatitis. Aggressive emollient use and a 2–3 L/day fluid target are the standard counter.
5. Skin infection vigilance. Patients on biologics already have a slightly elevated bacterial and fungal skin-infection risk. The GLP-1 itself does not add to this, but the weight-loss-induced skin-fold changes can shift intertriginous candida patterns — standard topical antifungal management.
6. Insurance and cost. GLP-1 prior authorization follows standard obesity-indication paths. The dermatology biologic side is unchanged — biologics run $30,000–$50,000/year list price with most major insurers covering for moderate-to-severe psoriasis, eczema, or PsA after step-edit.

Related research and tools

• GLP-1 in lupus and rheumatoid arthritis — the autoimmune-overlap pathway in detail
• GLP-1 + statin interactions — cardiometabolic stacking for the high-CV-risk psoriasis patient
• GLP-1 + SSRI interactions — depression comorbid with psoriasis is common; how the two classes coexist
• Ozempic and psoriasis or eczema — the semaglutide-specific signal in dermatology

Important disclaimer. This article is educational and does not constitute medical advice. Psoriasis, eczema, PsA, and HS are heterogeneous diseases; biologic and JAK-inhibitor selection should be coordinated between dermatology, rheumatology, and the prescribing obesity-medicine clinician. GLP-1 prescription decisions require an individual benefit-risk assessment; patients with a personal or family history of medullary thyroid carcinoma or MEN-2 should not use a GLP-1. PMIDs were verified live against the PubMed E-utilities API on 2026-05-29.

Last verified: 2026-05-29. Next review: every 12 months, or sooner if a dedicated RCT of semaglutide or tirzepatide in moderate-to-severe psoriasis with a biologic-stacking arm is published.